独家直击！新浪观影团送福利！《哆啦A梦：天空的理想乡》免费观影活动邀您参与

新浪观影团送福利！《哆啦A梦：天空的理想乡》免费观影活动邀您参与

北京，2023年5月23日 - 为庆祝动画电影《哆啦A梦：天空的理想乡》上映，新浪观影团特举办免费观影活动，诚邀广大影迷朋友们一起重温童年经典，感受梦幻冒险之旅！

本次活动将于5月28日（周日）在北京中影国际影城（党史馆影院）举行，放映时间为15:10-16:58。观影名额有限，先到先得！

如何参与：

1. 关注@新浪观影团
2. 转发活动微博并带话题 #新浪观影团# #哆啦A梦：天空的理想乡#
3. 点击下方【+参加活动】按钮，填写报名信息

活动奖品：

《哆啦A梦：天空的理想乡》电影票（每人1张）

获奖名单：

将于5月27日（周二）12:00在@新浪观影团 官微公布。

活动规则：

1. 每人只能使用一个微博账号参与活动，如发现使用多个账号恶意刷奖，将取消所有获奖资格。
2. 中奖者需于5月28日（周日）14:00前持本人身份证或有效证件前往中影国际影城（党史馆影院）办理签到领票手续，逾时将视为自动放弃获奖资格。
3. 本活动最终解释权归新浪观影团所有。

**《哆啦A梦：天空的理想乡》**是《哆啦A梦》剧场版的第42部作品，将于2023年5月28日在日本上映。影片讲述了大雄和哆啦A梦驾驶着具有时光跳跃机能的“时光齐柏林飞船”，为了寻找自古以来许多冒险家梦寐以求的亚特兰蒂斯和龙宫城等每个人都曾想像过的梦幻乌托邦，在空中展开了一场大冒险的故事。

本次免费观影活动不仅是为回馈广大影迷朋友们一直以来的支持，也是为了让更多人能够欣赏到这部优秀的动画电影。新浪观影团诚挚邀请您参与本次活动，一起重温童年经典，感受梦幻冒险之旅！

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.